EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis

Martin Wilkie iD, Olof Heimbürger iD, Charlotte de Leon iD, Ola Carlsson iD, Andrew Davenport iD, Stanley L-S Fan iD, Jennifer Allen iD, Giuseppe Castellano iD, Kristien Daenen, Jonathan Dick, Lavanya Kamesh, Flavia Cornacchia und 1 weitere

Journal of the American Society of Nephrology · 04.06.2026

DOI: 10.1681/asn.0000001152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 04.06.2026. Verfasst von Martin Wilkie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points The study assessed the efficacy and safety of steady concentration peritoneal dialysis using the Carry Life UF system in the home setting over 4 weeks. Treatment with the Carry Life UF system resulted in higher ultrafiltration volume, sodium removal, and glucose ultrafiltration efficiency compared with a 2.5% dextrose control exchange. The use of Carry Life UF in the home setting was well tolerated and safe, with no unexpected adverse events.

Background

Steady concentration peritoneal dialysis (PD) is a novel therapy for improved fluid management. We compared the efficacy and safety of steady concentration PD using the Carry Life UF system with a standard 2.5% dextrose continuous ambulatory peritoneal dialysis (CAPD) exchange in the home setting.

Methods

This is a prospective, multicenter, randomized, crossover study of adult patients on CAPD using 2–4 exchanges per day, with at least one daily 2.5% dextrose exchange. The home phase lasted 4 weeks for each study arm. During the Carry Life UF arm, one daily 2.5% dextrose exchange was replaced with a Carry Life UF treatment 3 days/wk (1.5% dextrose solution for PD fill, 11 or 15 g/h glucose dose) and a 1.5% dextrose exchange 4 days/wk. The primary outcome was difference in ultrafiltration (UF) volume with 5-hour Carry Life UF treatment versus 5-hour 2.5% dextrose exchange (control). Secondary outcomes included adverse events, peritoneal sodium removal, and glucose UF efficiency.

Results

A total of 19 participants (mean [SD] age 56 [15] years, six women, seven with diabetes) completed the study. Peritoneal solute transfer rate categories were fast four, average 12, and slow three. The UF volume primary outcome was met as Carry Life UF was superior to control in a prespecified superiority margin of 250 ml, mean increase 381 ml, 95% confidence interval (CI, 285 to 477). For the Carry Life UF total group (11 and 15 g/h cohorts analyzed together), mean (SD) UF volume was 513 (251) versus 132 (172) ml for the control. The secondary outcome peritoneal sodium removal was greater with Carry Life UF versus control (mean increase 43 mmol/exchange, 95% CI, 32 to 54). The secondary outcome glucose UF efficiency (UF volume in relation to glucose absorption) was enhanced with Carry Life UF versus control (mean increase 6.4 ml/g, 95% CI, 3.7 to 9.1). Two serious adverse events (peritonitis) occurred in the home phase, one episode in each study arm.

Conclusions

This 4-week home study of steady concentration PD using the Carry Life UF system demonstrated efficacy and safety. Clinical Trial registry name and registration number: NCT05874804.

Schlagwörter

Stichwörter der Autor:innen

clinical trialdialysiselectrolytesperitoneal dialysissodium (Na+) transportultrafiltration

Autor:innen und Institutionen

  • Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom.
  • Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Medical Unit Renal Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Triomed AB, Lund, Sweden.
  • UCL Centre for Kidney and Bladder Health, Royal Free Hospital, University College London, London, United Kingdom.
  • Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.

ORCID-Profile: Martin Wilkie, Olof Heimbürger, Charlotte de Leon, Ola Carlsson, Andrew Davenport, Stanley L-S Fan, Jennifer Allen, Giuseppe Castellano, Jörgen Hegbrant

Zitieren

APA

Wilkie, M., Heimbürger, O., de Leon, C., Carlsson, O., Davenport, A., Fan, S. L., Allen, J., Castellano, G., Daenen, K., Dick, J., Kamesh, L., Cornacchia, F., & Hegbrant, J. (2026). Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001152

Vancouver

Wilkie M, Heimbürger O, de Leon C, Carlsson O, Davenport A, Fan SL, et al. Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001152

BibTeX
@article{Wilkie2026,
  author = {Wilkie, Martin and Heimbürger, Olof and de Leon, Charlotte and Carlsson, Ola and Davenport, Andrew and Fan, Stanley L-S and Allen, Jennifer and Castellano, Giuseppe and Daenen, Kristien and Dick, Jonathan and Kamesh, Lavanya and Cornacchia, Flavia and Hegbrant, Jörgen},
  title = {Ultrafiltration and Sodium Removal in Steady Concentration Peritoneal Dialysis},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001152}
}
Kostenlos starten →